Medicare now negotiating price of drug that costs $7,100 in U.S. vs. $900 in Canada
CTV
Sen. Bernie Sanders is once again taking the pharmaceutical industry to task, issuing a report Tuesday that highlights the cost of three blockbuster drugs that are far pricier in the U.S. than in other countries.
Sen. Bernie Sanders is once again taking the pharmaceutical industry to task, issuing a report Tuesday that highlights the cost of three blockbuster drugs that are far pricier in the U.S. than in other countries.
The differences are striking. The annual list price of Bristol Myers Squibb’s Eliquis, a blood thinner that reduces the risk of stroke, is $7,100 in the U.S. But in Japan, it’s US$940; in Canada, it’s US$900; in Germany, it’s US$770; in the United Kingdom, it’s US$760; and in France, it’s US$650.
Johnson & Johnson’s arthritis drug Stelara carries an annual list price of $79,000 in the U.S. In Germany, it’s US$30,000; in Canada, it’s US$20,000; in the U.K., it’s US$16,000; in Japan, it’s US$14,000; and in France, it’s US$12,000.
And the annual list price of Merck’s cancer drug Keytruda is $191,000 in the US, while in the U.K., it’s US$115,000; in Canada, it’s US$112,000; in France, it’s US$91,000; in Germany, it’s $89,000; and in Japan, it’s US$44,000.
Sanders, an independent from Vermont, issued the report ahead of a hearing Thursday with the CEOs of the three drugmakers before the Senate Committee on Health, Education, Labor and Pensions, which he chairs. The hearing has already proved fiery, with Sanders threatening to issue the committee’s first subpoenas in more than 40 years to compel the heads of Johnson & Johnson and Merck to testify. They agreed late last month to appear voluntarily.
Johnson & Johnson declined to comment on Sanders’ report. Merck and Bristol Myers Squibb did not return requests for comment.
Other nations typically pay far less for medications, in large part because their governments often determine the cost. However, that gap could begin to shrink for certain drugs in coming years.
Despite the delays for the NASA’s Artemis II mission around the moon and back, a space medicine researcher says the crew, which includes Canadian astronaut Jeremy Hansen, are physically ready for when the time comes to launch.
If a teen is interested in losing weight, chances are they may turn to artificial intelligence platforms to get advice.
The public downfall this week of Denmark’s Rene Redzepi, arguably the world’s top chef, has forced a reckoning in real time over when “brigade de cuisine” becomes abuse and what should happen to perpetrators who direct the creation of edible art.
A new study suggests climate change is doing something few people could ever notice: it’s making Earth’s days slightly longer.
Artificial intelligence is taking some of the discomfort out of trying to perfect your resume, but the growing use of the technology in job applications is creating new challenges for employers trying to sort through candidates and figure out who they’re really dealing with.
An expert on body image is warning of a new social media trend that is sending a negative message to boys and men.
Japan's stunning Seto Inalnd Sea offers a wonderful collection of art, history and luxury to travelers looking beyond the country's iconic sites.
Peel Public Health says nearly 16,000 students in the region could be suspended due to incomplete immunization records.
On Thursday morning, 68-year-old Mava Brydges put the weight of a household refrigerator onto her back, lowered herself toward the floor and then stood up again.
At this month’s Milan Cortina Paralympics, some athletes competed in shorts, T-shirts and tank tops. One skier lamented “tropical” conditions and a snowboarder complained that soft, slow snow put him at a disadvantage. And some worried about their safety.
Ottawa is expected to announce $552 million in funding for academic research projects this morning.
Two people are dead after donating plasma at Winnipeg collection centres.